Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Yutong Li 0006

dblp:55/10759-6 · DBLP profile ↗
← Back
2ranked-venue papers
2as first author
2since 2021 · last 2024
0000-0003-4420-4518ORCID · verified

Domains — the database's venue-derived domains; a paper can count in several

Artificial intelligence and machine learning · 1 · 1 first-author · 1 since 2021Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 4 heaviest of 5, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery
drug design
0.812024
CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024
Bioinformatics and computational biology › drug discovery › drug design
fragment-based drug design
0.812024
CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024
Bioinformatics and computational biology › drug discovery › drug design
ligand design
0.812024
CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024
Bioinformatics and computational biology › molecular informatics › cheminformatics
molecule generation
0.812024
CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024

Methods — techniques the papers use, named apart from their topics

variational autoencoder · 0.8multi-objective optimization · 0.8molecular docking · 0.8
YearPublicationVenuePosition
2024 Optimisation-based modelling for explainable lead discovery in malaria
abstract
BACKGROUND: The search for new antimalarial treatments is urgent due to growing resistance to existing therapies. The Open Source Malaria (OSM) project offers a promising starting point, having extensively screened various compounds for their effectiveness. Further analysis of the chemical space surrounding these compounds could provide the means for innovative drugs. METHODS: We report an optimisation-based method for quantitative structure-activity relationship (QSAR) modelling that provides explainable modelling of ligand activity through a mathematical programming formulation. The methodology is based on piecewise regression principles and offers optimal detection of breakpoint features, efficient allocation of samples into distinct sub-groups based on breakpoint feature values, and insightful regression coefficients. Analysis of OSM antimalarial compounds yields interpretable results through rules generated by the model that reflect the contribution of individual fingerprint fragments in ligand activity prediction. Using knowledge of fragment prioritisation and screening of commercially available compound libraries, potential lead compounds for antimalarials are identified and evaluated experimentally via a Plasmodium falciparum asexual growth inhibition assay (PfGIA) and a human cell cytotoxicity assay. CONCLUSIONS: Three compounds are identified as potential leads for antimalarials using the methodology described above. This work illustrates how explainable predictive models based on mathematical optimisation can pave the way towards more efficient fragment-based lead discovery as applied in malaria.
Yutong Li 0006, Jonathan Cardoso-Silva, John M. Kelly, Michael J. Delves, Nicholas Furnham, Lazaros G. Papageorgiou, Sophia Tsoka
Artif. Intell. Medicine1
2024 CLigOpt: controllable ligand design through target-specific optimization
abstract
MOTIVATION: A key challenge in deep generative models for molecular design is to navigate random sampling of the vast molecular space, and produce promising molecules that strike a balance across multiple chemical criteria. Fragment-based drug design (FBDD), using fragments as starting points, is an effective way to constrain chemical space and improve generation of biologically active molecules. Furthermore, optimization approaches are often implemented with generative models to search through chemical space, and identify promising samples which satisfy specific properties. Controllable FBDD has promising potential in efficient target-specific ligand design. RESULTS: We propose a controllable FBDD model, CLigOpt, which can generate molecules with desired properties from a given fragment pair. CLigOpt is a variational autoencoder-based model which utilizes co-embeddings of node and edge features to fully mine information from molecular graphs, as well as a multi-objective Controllable Generation Module to generate molecules under property controls. CLigOpt achieves consistently strong performance in generating structurally and chemically valid molecules, as evaluated across six metrics. Applicability is illustrated through ligand candidates for hDHFR and it is shown that the proportion of feasible active molecules from the generated set is increased by 10%. Molecular docking and synthesizability prediction tasks are conducted to prioritize generated molecules to derive potential lead compounds. AVAILABILITY AND IMPLEMENTATION: The source code is available via https://github.com/yutongLi1997/CLigOpt-Controllable-Ligand-Design-through-Target-Specific-Optimisation.
Yutong Li 0006, Pedro H. C. Avelar, Xinyue Chen 0009, Min Wu 0008, Sophia Tsoka
Bioinform.1